Market research
MBG.F Marinomed Biotech AG
F EUR Consumer Cyclical
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 39B
- P/E ratio
- 7.72
- Analyst target
- 51.1575
- Dividend yield
- 8.6%
- Beta
- 0.75
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Consumer Cyclical
- Industry
- Auto Manufacturers
- ISIN
- DE0007100000
- Market cap
- 39B
- P/E ratio
- 7.72
- Analyst target
- 51.1575
- Dividend yield
- 8.6%
- Beta
- 0.75
About
About Marinomed Biotech AG
Mercedes-Benz Group AG operates as an automotive company in Europe, Germany, North America, the United States, Asia, China, and internationally. It operates through Mercedes-Benz Cars, Mercedes-Benz Vans, and Mercedes-Benz Financial Services segments. The company develops, manufactures, and sells cars and vans under the Mercedes-Benz, Mercedes-AMG, Mercedes-Maybach, G-Class brands, as well as related spare parts and accessories. It also provides financing, leasing, vehicle subscription and rental, fleet management, insurance, and digital services related to charging electric vehicles. The company was formerly known as Daimler AG and changed its name to Mercedes-Benz Group AG in February 2022. Mercedes-Benz Group AG was founded in 1886 and is headquartered in Stuttgart, Germany.
Research context
Marinomed Biotech AG appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Consumer Cyclical
- Industry
- Auto Manufacturers
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the MBG.F discussion.
5 years, 7 months ago
Marinomed Biotech AG is currently in a long term downtrend where the price is trading 0.7% below its 200 day moving average.
From a valuation standpoint, the stock is 98.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 25.8.
Marinomed Biotech AG's total revenue rose by 67.7% to $3M since the same quarter in the previous year.
Its net income has dropped by 24.7% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 351.3% to $-3M since the same quarter in the previous year.
Based on the above factors, Marinomed Biotech AG gets an overall score of 2/5.